SCARB2

Across TCGA pan-cancer cohorts, SCARB2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SCARB2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SCARB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCARB2 expression acts as an unfavorable survival marker.

LSCC, GBM, and PDAC are the cancer types where SCARB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.541	0.873	.001	22	view →
GBM	DFS	Quartile	All	0.624	0.900	<.001	18	view →
PDAC	DFS	Quartile	All	0.679	0.874	.012	16	view →
OV	DFS	Median	All	0.650	0.923	.029	8	view →
LUAD	DFS	Tertile	All	0.838	0.973	.017	7	view →
COAD	DFS	Median	All	0.884	1.000	.017	6	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SCARB2–LSCC (DFS)

Open the LSCC breakdown →